{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T03:51:46Z","timestamp":1648525906565},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1157\/13102263","type":"journal-article","created":{"date-parts":[[2007,5,31]],"date-time":"2007-05-31T13:35:55Z","timestamp":1180618555000},"page":"297-299","source":"Crossref","is-referenced-by-count":1,"title":["Short-course regimens for latent tuberculosis: what is ready for prime time?"],"prefix":"10.1016","volume":"25","author":[{"given":"William","family":"J. Burman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13102263_bib1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1164\/rccm.200510-1667OC","article-title":"Predicting non-completion of treatment for latent tuberculous infection: a prospective survey","volume":"174","author":"Shieh","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13102263_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1164\/ajrccm.159.1.9807020","article-title":"A tuberculin screening and isoniazid preventive therapy program in an inner-city population","volume":"159","author":"Bock","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13102263_bib3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","article-title":"Use of isoniazid for latent tuberculosis infection in a public health clinic","volume":"168","author":"LoBue","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13102263_bib4","first-page":"13","article-title":"Adherence to anti-tuberculosis chemoprophylaxis and treatment in children","volume":"10","author":"Van Zyl","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1157\/13102263_bib5","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/00002030-200111090-00009","article-title":"Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults","volume":"15","author":"Johnson","year":"2001","journal-title":"AIDS"},{"key":"10.1157\/13102263_bib6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/00002030-199903110-00009","article-title":"Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials","volume":"13","author":"Bucher","year":"1999","journal-title":"AIDS"},{"key":"10.1157\/13102263_bib7","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1164\/ajrccm\/148.6_Pt_1.1541","article-title":"Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice","volume":"148","author":"Ji","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1157\/13102263_bib8","first-page":"1080","article-title":"Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis","volume":"10","author":"Gao","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1157\/13102263_bib9","first-page":"276","article-title":"Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?","volume":"9","author":"Tortajada","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1157\/13102263_bib10","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-137-8-200210150-00007","article-title":"Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial","volume":"137","author":"Jasmer","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1157\/13102263_bib11","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1086\/499244","article-title":"Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection","volume":"42","author":"Ijaz","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13102263_bib12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1157\/13102265","article-title":"Ensayo cl\u00ednico aleatorizado para evaluar tres pautas cortas de tratamiento de la infecci\u00f3n latente tuberculosa en pacientes infectados por el VIH","volume":"25","author":"Rivero","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1157\/13102263_bib13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1086\/422724","article-title":"Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?","volume":"39","author":"Gordin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13102263_bib14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199709183371201","article-title":"A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration","volume":"337","author":"Whalen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1157\/13102263_bib15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1157\/13102264","article-title":"Pauta corta de isoniacida y rifampicina comparada con isoniacida para la infecci\u00f3n latente de tuberculosis. Ensayo cl\u00ednico aleatorizado","volume":"25I 5","author":"Geijo","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1157\/13102263_bib16","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/427802","article-title":"Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis","volume":"40","author":"Ena","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13102263_bib17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months","volume":"170","author":"Menzies","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13102263_bib18","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.200512-1953OC","article-title":"Weekly rifapentine\/isoniazid or daily rifampin\/pyrazinamide for latent tuberculosis in household contacts","volume":"173","author":"Schechter","year":"2006","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X07742891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X07742891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,6]],"date-time":"2019-01-06T19:27:07Z","timestamp":1546802827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X07742891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0213005X07742891"],"URL":"https:\/\/doi.org\/10.1157\/13102263","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}